Cargando…

Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders

Detalles Bibliográficos
Autores principales:	Harrington, Patrick, Kurshan, Ashwini, Delord, Marc, Lechmere, Thomas, Sheikh, Amna, Saunders, Jamie, Saha, Chandan, Dillon, Richard, Woodley, Claire, Asirvatham, Susan, Curto-Garcia, Natalia, Sullivan, Jennifer O’, Kordasti, Shahram, Radia, Deepti, McLornan, Donal, Malim, Michael H., Harrison, Claire, Doores, Katie J., de Lavallade, Hugues
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472701/ https://www.ncbi.nlm.nih.gov/pubmed/36083126 http://dx.doi.org/10.1182/bloodadvances.2022008375

Ejemplares similares

Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
por: Harrington, Patrick, et al.
Publicado: (2022)

P990: T CELL RESPONSE AND OMICRON VARIANT NEUTRALISATION FOLLOWING VACCINATION AGAINST SARS-COV-2 IN PATIENTS WITH CHRONIC MYELOID DISORDERS
por: Harrington, P., et al.
Publicado: (2022)

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib
por: Harrington, Patrick, et al.
Publicado: (2022)

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
por: Harrington, Patrick, et al.
Publicado: (2021)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
por: Harrington, P., et al.
Publicado: (2022)

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia
por: Harrington, Patrick, et al.
Publicado: (2021)

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)
por: Okikiolu, Jumoke, et al.
Publicado: (2022)

Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients
por: Harrington, Patrick, et al.
Publicado: (2021)

Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients
por: Harrington, Patrick, et al.
Publicado: (2021)

Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients
por: Harrington, Patrick, et al.
Publicado: (2021)

Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral Center
por: Khan, Alesia, et al.
Publicado: (2021)

Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021
por: Saunders, Jamie, et al.
Publicado: (2021)

Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia
por: Harrington, Patrick, et al.
Publicado: (2023)

Ruxolitinib for the Treatment of Essential Thrombocythemia
por: Gunawan, Arief, et al.
Publicado: (2018)

Bone marrow niche dysregulation in myeloproliferative neoplasms
por: Curto-Garcia, Natalia, et al.
Publicado: (2020)

Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?
por: McLornan, Donal, et al.
Publicado: (2013)

The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern
por: Graham, Carl, et al.
Publicado: (2022)

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
por: Bassiony, Sarah, et al.
Publicado: (2020)

Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
por: Seow, Jeffrey, et al.
Publicado: (2023)

JAK2 V617F: A Single Mutation in the Myeloproliferative Group of Disorders
por: McLornan, Donal, et al.
Publicado: (2006)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
por: McLornan, Donal P., et al.
Publicado: (2019)

Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals
por: Lechmere, Thomas, et al.
Publicado: (2022)

Intravesical recurrence of chromophobe renal cell carcinoma
por: Kelly, Niall P., et al.
Publicado: (2023)

Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms
por: Contreras Castillo, Stephania, et al.
Publicado: (2021)

Urosepsis and the urologist!
por: Ryan, James, et al.
Publicado: (2021)

Implementation of telemedicine in response to COVID-19 in a Dublin hospital - A patient perspective
por: Horan, M., et al.
Publicado: (2021)

Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis
por: Perram, Jacinta, et al.
Publicado: (2022)

Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals
por: Kurshan, Ashwini, et al.
Publicado: (2023)

Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
por: McKenzie, Duncan R., et al.
Publicado: (2022)

RPL27A is a target of miR-595 and may contribute to the myelodysplastic phenotype through ribosomal dysgenesis
por: Alkhatabi, Heba A., et al.
Publicado: (2016)

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review
por: Ianotto, Jean-Christophe, et al.
Publicado: (2019)

Comparative Efficacy of Three Forms of Parenteral Iron
por: Dillon, Richard, et al.
Publicado: (2012)

Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy—Is it prognostic?—a single-center retrospective study
por: Sheth, Vipul, et al.
Publicado: (2021)

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline
por: McMullin, Mary F. F., et al.
Publicado: (2018)

The Role of Early Molecular Response in the Management of Chronic Phase CML
por: Harrington, Patrick, et al.
Publicado: (2017)

The impact of COVID-19 on acute urinary stone presentations: a single-centre experience
por: Anderson, Steven, et al.
Publicado: (2021)

The impact of COVID-19 on acute urinary stone presentations: A single centre experience
por: Anderson, S., et al.
Publicado: (2021)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
por: Mesa, Ruben, et al.
Publicado: (2022)

Anemia management: development of a rapidaccess anemia and intravenous iron service
por: Radia, Deepti, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_a1l5j5eu8dl47c70907il2hbua